Clinical Trial

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-09-16; most recent amendment 2026-06-03.
Status change: Not Yet Recruiting → Recruiting 2025-11-26
Trial Details
NCT Number NCT07187973
Lead Sponsor Disc Medicine, Inc
Conditions Sickle Cell Disease
Enrollment 24 participants
Start Date 2026-01-06
Primary Completion 2027-06 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-30